Navigation Links
Prostate Cancer Test a Flop in Study
Date:5/3/2010

Doesn't distinguish aggressive tumors from slow-moving malignancies

MONDAY, May 3 (HealthDay News) -- A technique that urologists had hoped would make it possible to distinguish men with prostate cancer who need treatment from those who would only need watchful waiting didn't work well, researchers report.

The technique, called PSA kinetics, measures changes in the rate at which the prostate gland produces a protein called prostate-specific antigen. A significant increase in PSA kinetics, measured by the time during which PSA production doubles or increases at a rapid rate, is supposed to indicate the need for treatment, by radiation therapy or surgery.

PSA kinetics has long been used to measure the effectiveness of treatment. A number of cancer centers have started to use it as a possible method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be left alone.

Recent studies indicating that many men with slow-growing prostate cancers undergo unnecessary treatment have given urgency to the search for such a tool, especially considering that side effects of treatment can include incontinence and impotence.

But the study indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr. Ashley E. Ross, a urology resident at the Johns Hopkins University Brady Urological Institute, and lead author of a report on the technique published online May 3 in the Journal of Clinical Oncology.

The report describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer -- the kind that often doesn't require treatment -- for an average of 2.9 years. The results of PSA tests were compared with biopsies -- tissue samples -- that measured the progression of the cancers.

The trial is part of a study, under supervision of Dr. H. Ballentine Carter, director of the division of adult urology at the Brady Urological Institute, that began in 1994. Men in the trial had PSA tests every six months and biopsies every year.

"PSA values do not predict progression by biopsy," Ross said. "There were huge overlaps between people who had higher or lower values. They were not predictive of if you had more disease or more aggressive disease."

And so the findings do not support the hope that PSA kinetics might lessen the need for frequent biopsies, Ross said. "You need to biopsy these men yearly or less than that," he said.

But the issue is still open, said Dr. Jared Whitson, a clinical instructor in urology at the University of California, San Francisco, who wrote an accompanying editorial.

There might have been "selection bias" in the study, Whitson said, since many men under watchful waiting at the institute were not included in the trial. "We don't know a lot about the 300 patients who were in active surveillance but not included in the trial," he said.

In addition, "there is some prior evidence to suggest that PSA kinetics are associated with biopsy progression," Whitson said.

There was such evidence in a Canadian trial, Ross acknowledged, but "in the Canadian study there were men with a lot more cancer than we would be comfortable following. We only select men with very little cancer."

So it is too early to give up on PSA kinetics as a method of determining who should be treated, Whitson said. But it is only one of the tools that should be used to make a decision, he said. "There is no one feature or factor which can singlehandedly prompt intervention," Whitson said. Other standard markers, such as Gleason score, a measure of a cancer's degree of disorganization, must also be used, he said.

More information

For a complete rundown on prostate cancer, visit the U.S. National Cancer Institute.



SOURCES: Ashley E. Ross, M.D., Ph.D., urology resident, Johns Hopkins University, James Buchanan Brady Urological Institute, Baltimore; Jared Whitson, M.D., clinical instructor, urology, University of California, San Francisco; May 3, 2010, Journal of Clinical Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Reviews Side Effects From Prostate Cancer Therapy
2. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
3. FDA Approval of new Prostate Treatment Shows Promise of Cancer Immunotherapy
4. Prostate Cancer Vaccine Gains FDA Approval
5. Prostate Cancer Vaccine May Get FDA Approval
6. Prostate cancer: Risk increases with the number of affected family members
7. ASTRO president speaks on prostate cancer at MEDCAC meeting
8. Does the weather cause northerners to get more prostate cancer?
9. Weather Might Influence Prostate Cancer
10. Weight Gain, Smoking May Make Prostate Cancer Deadlier
11. Weight Gain, Smoking May Make Prostate Cancer More Deadly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... “Beyond and Back”: a true-life testimony of tragedy and the ... author Bonetta Rose, a wife, mother and grandmother committed to sharing her many spiritual ... Bonetta Rose‘s new book presents actual events in the life of her family, which ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To ... Response To Atheist Manifesto” is the creation of published author Richard Hostetter, a ... sixty years. He holds graduate degrees from Kent State University and the University ...
(Date:3/22/2017)... ... March 23, 2017 , ... Death anxiety is unconscious and needs understanding and ... was inspired to write the book titled “ As Good as Goodbyes Get ” ... sense of what she was experiencing at the bedside of patients who were dying. ...
(Date:3/22/2017)... Jose, CA (PRWEB) , ... March 22, 2017 ... ... San Jose, Santa Cruz and Milpitas with a robust, ongoing community enrichment program, ... Housing (FSH), a nonprofit organization which has provided for the critical needs of ...
(Date:3/22/2017)... Ramon, CA (PRWEB) , ... March 22, 2017 ... ... tissue recovery agency for northern California and Nevada and LABS, Inc., announced the ... rapid turnaround (STAT) infectious disease screening and serology testing used to determine ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 ... that it has completed the acquisition of Cynosure, Inc., ... $66 per share in cash. "We are ... forward to working with Michael Davin and ... in the large, rapidly growing medical aesthetics market," said ...
(Date:3/22/2017)... NEW YORK , March 22, 2017 ... Electrophysiology (EP) market is growing rapidly due to the ... a report published by Allied Market Research, the global ... is expected to reach $8.271 billion by 2022, with ... cardiology and is used to diagnose abnormal heartbeats or ...
(Date:3/22/2017)... March 22, 2017  As the world,s leading non-profit ... Society (LLS) has played a role in most therapies ... which are even helping patients with other cancers and ... significant investment in cutting-edge research – more than $1 ... grow with the record-breaking sum of $4.1 million raised ...
Breaking Medicine Technology: